Tumour growth is dependent on angiogenesis, the key mediator of which is vascular endothelial growth factor-A (VEGF-A). VEGF-A exists as two families of alternatively spliced isoformspro-angiogenic VEGF xxx generated by proximal, and anti-angiogenic VEGF xxx b by distal splicing of exon 8. VEGF 165 b inhibits angiogenesis and is downregulated in tumours. Here, we show for the first time that administration of recombinant human VEGF 165 b inhibits colon carcinoma tumour growth and tumour vessel density in nude mice, with a terminal plasma half-life of 6.2 h and directly inhibited angiogenic parameters (endothelial sprouting, orientation and structure formation) in vitro. Intravenous injection of 125 I-VEGF 165 b demonstrated significant tumour uptake lasting at least 24 h. No adverse effects on liver function or haemodynamics were observed. These results indicate that injected VEGF 165 b was taken up into the tumour as an effective anti-angiogenic cancer therapy, and provide proof of principle for the development of this anti-angiogenic growth factor splice isoform as a novel cancer therapy.
Introduction
Vascular endothelial growth factor-A (VEGF) is the principal angiogenic promoter in most, if not all, cancers. VEGF is upregulated by hypoxia,1 and by over-expression of oncogenes in tumours,2 and stimulates the migration of endothelial cells, sprouting of blood vessels and generation of new vessels from existing vasculature in tumours (reviewed in3), resulting in sustained blood flow, oxygen supply and waste removal to the growing tumour. Anti-VEGF therapy has been hailed as the fourth line of cancer treatment alongside surgery, chemotherapy and radiotherapy, and antibodies to VEGF have shown clinical benefit in colorectal cancer, renal carcinoma, non-small cell lung cancer, breast cancer4,5 and are in further phase III clinical trials in other cancers.
VEGF is generated as multiple isoforms by alternative splicing of mRNA from 8 exons. Alternate splicing of exons 6 and 7 results in proteins with differing heparin binding affinity, and numbers of amino acids, such as VEGF 165 , VEGF 121 and VEGF 189 , termed according to the number of amino acids encoded in the final secreted protein. Alternate splicing into the terminal exon, exon 8, gives rise to two families of isoforms, the VEGF xxx b and VEGF xxx isoforms. The VEGF xxx b family of isoforms, first identified in 2002,6 are generated by the use of a more distal 3′ splice acceptor site, and result in mRNA species that code for proteins of the same length as the VEGF xxx isoforms, but with different C-terminal six amino acids. Whereas the VEGF xxx isoforms (e.g. VEGF 165 and VEGF 121 ) are proangiogenic and are upregulated in tumours, the VEGF xxx b isoforms (e.g. VEGF 165 b and VEGF 121 b) are anti-angiogenic and downregulated in tumours.6,7 This anti-angiogenic activity is generated by receptor binding,7,8 but only weak receptor activation, and inhibition of downstream VEGFR2 signalling.7 Its activity has led to the hypothesis that VEGF 165 b may be a useful therapeutic tool in angiogenic conditions such as in tumour growth, or in neovascularisation associated with retinopathy9 such as in diabetes.
To determine whether VEGF 165 b has an appropriate pharmacokinetic profile for systemic anti-angiogenic therapy, we have investigated the clearance rates, toxicity, tumour uptake and circulating effects on blood pressure of VEGF 165 b injection in mice, and whether recombinant human VEGF 165 b exerts inhibitory effects on tumour growth in tumourbearing mice.
Materials and methods

Production of recombinant protein
Recombinant human VEGF 165 b (rhVEGF 165 b), produced in Chinese Hamster Ovary Cells with correct glycosylation, dimerisation and receptor binding, was generated by Cancer Research Technologies, London, United Kingdom or PPS, Israel. Protein was analysed by MALDI-TOF mass spectrometry (Voyager DE-STR, Applied Biosystems, Foster City, CA). Endotoxins were removed by phase separation using Triton X-114 followed by endotoxin detection using Limulus Amebocyte Lysate performed by Cambrex (Cambrex Corporation). All the proteins were considered endotoxin free (endotoxin levels below 5 EU/ml of concentrated stock). Recombinant canine VEGF 165 (rcVEGF 165 ) or rcVEGF 165 b was produced and assayed for retained activity as previously described.8
Functional effects of recombinant VEGF 165 b
Human umbilical vein endothelial cells (HUVEC) were extracted from umbilical cords from caesarean sections (St. Michael's Hospital, Bristol, UK). HUVECs were maintained in M200 supplemented with low serum growth factor supplements (Cascade Biologics, Portland, OR) in flasks coated with extracellular matrix proteins. Cells were used at passages 3-5. Sub-confluent HUVECs were serum starved for 7 h in M200 medium without supplement, and 100,000 serum starved cells were plated into collagen-coated 8 μm inserts (Millipore, Billerica, MA). Inserts were placed in 24-well plates with 500 μl of chemoattractant in M200 medium with 0.1% v/v FCS and 0.2% w/v BSA and incubated overnight at 37 °C to allow for migration. After incubation, inserts were washed, nonmigrated cells were removed and migrating cells were stained in Mayer's haematoxylin. Migrating cells were counted (10 fields per insert) and expressed either as a relative change to basal migration (media without chemoattractant) or% migration and plotted as average ± s.e.m. Experiments were performed in triplicate.
To determine the concentration at which 50% of the migratory response was inhibited, (IC 50 ), increasing amounts of VEGF 165 b were added (1-100 ng/ml) with or without the optimal concentration of 40 ng/ml of VEGF 165 . For stability tests, recombinant VEGF 165 b was incubated under sterile conditions at 37 °C for 1 or 2 weeks, whereafter the retained inhibitory migratory response was assayed.
Angiogenesis assay
Extracellular matrix gel solution was prepared according to manufacturer's instructions (Chemicon International, Temecula CA). Thirty microlitre gel solution was transferred to each well of pre-cooled 8-well culture slides (Falcon, BD, Oxford, Oxfordshire, UK) and incubated at 37 °C to solidify. VEGF 165 , VEGF 165 b and the combination were placed on one side of the gel to 1 nM final concentration. Human Microvascular Endothelial Cells, HMVEC, were serum starved for 3 h with EBM-2 (Clonetechs, Lonza), and 10,000 cells were seeded onto the gel in 100 μl EBM-2 basal media and incubated at 37 °C for 6 h. Gels were fixed in 4% w/v para-formaldehyde/PBS pH 7.4 for 5 min and washed twice with PBS. F-actin fibres were stained with Alexa 488 phalloidin for 1 h (Molecular Probes, dilution 1:200 in PBS/0.5% v/v Triton) and 10 min with Hoechst 33342 (5 μg/ml PBS/0.5% v/v Triton). Gels were washed twice with PBS/0.5% v/v Triton, twice with PBS and mounted with vectashield (Vector Laboratories Burlingame, CA). Images were taken on a Leica DM RB fluorescence microscope for structure analysis counting branch points, sprouts and closed polygons over the entire area of the well.
Injections of recombinant human VEGF 165 b into LS174t tumour-bearing mice
LS174t colon carcinoma cells (2 × 10 6 ) in 200 μl sterile PBS were injected into the nape of the neck of nude mice and injected with rhVEGF 165 b subcutaneously every day or twice weekly (in 200 μl 0.9% w/v NaCl), starting 24 h after the injection of tumour cells (prophylactic) or when tumours reached a diameter of 4-5 mm (therapeutic). Bi-weekly intraperitoneal injection was carried out in mice 4 d after the injection of 2 × 10 6 LS174t tumour cells as above. Xenotransplanted tumours were measured by calliper every day, and tumour volume was calculated according to (length × width × [length + width]/2). Mice were culled by cervical dislocation and organs and tumours were removed. Tumour vessel density was counted in 10 random fields (magnification 40x) in haematoxylin and eosin stained 6 μm frozen sections from tumours. Vessel presence was confirmed by staining by blocking in 5% v/v goat Ig for 30 min, 2 μg/ml PECAM-1 antibody (Santa Cruz, sc-1505) or 1 μg/ml Flk-1 (Santa Cruz sc-6251) overnight, 2 μg/ml anti-goat or anti-mouse biotin antibody (Vector Laboratories) for 1 h followed by avidin-biotinylated enzyme complex (ABC, Vector Laboratories) for 30 min followed by DAB substrate (Vector Laboratories). Sections were examined using a Nikon Eclipse E400 microscope and photos were captured using Nikon Eclipse Net software. Area of necrosis was scored in similar way as above by circling necrotic area, calculated from the lighter staining pattern of the haematoxylin and eosin, compared to whole tumour area using Open Lab.
Animal injections and collection of samples
C57/Bl6 mice (body weight >20 g) were kept on a heating mat under anaesthesia using 500 μg/kg medetomidine hydrochloride (Domitor, Pfizer, Tadworth, Surrey, UK) and 50 mg/kg ketamine (Vetalar V, Pharmacia, Tadworth, Surrey, UK) for intravenous injection and cardiac puncture according to UK Home Office regulations. Local anaesthetic cream (EMLA, Astra Zeneca, Macclesfield, Cheshire, UK) was added to the tail when collecting blood from the tail vein, and each mouse was bled (max 100 μl) only once every 24 h. For each time point at least 3 mice were used and for experiments less than 24 h, multiple mice groups were used with 3 mice in each group. During intraperitoneal and subcutaneous injections, mice were not anaesthetised but monitored for discomfort and pain. Blood was collected under general anaesthesia, as above either through the tail vein or through cardiac puncture into EDTA vacutainers (BD, Oxford, Oxfordshire, UK) and centrifuged at 3,000 rpm at 4 °C for 10 min, and plasma was transferred to a fresh tube and stored at -20 °C.
Mini pumps (Alzet, Kent, UK) with infusion rate of 208 ng/h(5 μg/24 h) for 14 d were implanted subcutaneously into C57/Bl6 mice under isofluorane anaesthesia. Mice were then sutured using Mersilk 6.0 (Ethicon, Johnson-Johnson, Ascot, Berkshire, UK). Mice were given an intramuscular injection of 50 μg/kg Temgesic (Schering-Plough, Hertfordshire, UK). Recombinant protein was diluted in sterile 0.9% w/v NaCl, and injection volumes were 100-200 μl as appropriate for the injection site. Mice were culled by cervical dislocation or exsanguinated under anaesthesia and organs were removed and snap-frozen in liquid nitrogen.
ELISA for VEGF 165 b or VEGF 165 in plasma
An in-house ELISA specific for VEGF 165 b has been developed and described elsewhere.7 All the reagents were from R&D Systems (Abingdon, Oxfordshire, UK) if not otherwise stated. Briefly, immulon 2HB 96-well plates (Thermo Scientific, Basingstoke, UK) were coated with 0.8 μg/ml goat anti-hVEGF capture antibody and blocked with 5% w/v BSA followed by the addition of samples. Detection was done by the addition of biotinylated mouse monoclonal anti-VEGF 165 b antibody at 0.4 μg/ml followed by incubation with horseradish peroxidase-conjugated streptavidin and substrate development before being read at 450 nm and 570 nm for reference.
For rhVEGF 165 , rcVEGF 165 and rcVEGF 165 b, a commercial panVEGF ELISA was used according to manufacturer's protocol (Duoset VEGF ELISA, R&D Systems, Minneapolis, MN). Plasma samples were diluted 1:10 and run in duplicates or triplicates.
In vivo imaging of 125 I-rhVEGF 165 b biodistribution
Nude mice were injected with LS174t tumours on the right hindleg. 125 I-rhVEGF 165 b was generated using Iodogen™ tubes (Pierce Biotechnology Inc.) and purified with NAP-10 columns (GE Healthcare). Analysis by thin layer chromatography revealed >95% purity. 125 I-rhVEGF 165 b ( 125 I-rhVEGF 165 b/total 125 I). 3.2 MBq (70 μg protein) was injected into the tail vein when tumours were >10 mm in diameter. Anaesthesia was maintained by 2% halothane during X-ray and scanning (NanoSPECT/CT, Bioscan, Washington, DC), after 40, 70, 120, 240 or 1440 min. For biodistribution studies, 0.100 MBq (3 μg) 125 I-rhVEGF 165 b was injected into the tail vein, and mice were culled at 120 or 240 min. Organs and tissues of interest were excised and assessed using a gamma counter (LKB Wallac 1282 Compugamma CS, Wallac). Uptake was expressed as% injected dose/g tissue. Rennel 
Toxicology analysis
Snap-frozen livers from nude mice injected daily with 5 or 10 μg VEGF 165 b for 14 d were embedded into O.C.T. compound (Sakura Finetek, Zoeterwoude, Netherlands), and 6 μm cryosections were fixed in ice-cold methanol and stained using conventional haematoxylin and eosin staining.
Liver enzyme function was analysed in plasma from C57/Bl6 mice daily injected with 5 μg VEGF 165 b 0.9% w/v saline (vehicle control) for 8 d. Plasma was collected and analysed by Langford Veterinary Diagnostics, Bristol, UK, for liver enzyme activity (ALT = alanine transaminase, ALP = alkaline phosphatase and GGT = gamma glutamyl transpeptidase).
SDS-PAGE and immunoblotting of tissue and cell lysate
Tissue lysate from mouse organs or cells was extracted using RIPA buffer (50 mM Tris, 150 mM NaCl, 1% v/v NP-40, 0.25% w/v Na-deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, 1 μg/ml of each of aprotinin, pepstatin and leupeptin) and homogenised using a polytron and spun at 12,000 rpm for 10 min at 4 °C. Lysates were separated on 7.5 or 15% SDS-PAGE, transferred to polyvinylidene fluoride membranes, blocked in 10% w/v dry milk, incubated with a biotinylated mouse monoclonal anti-human VEGF 165 b antibody (0.5 μg/ml) followed by horseradish peroxidase-conjugated streptavidin (1/500, R&D Systems), 200 ng/ml Flt-1 antibody (Santa Cruz, sc-316-G) and 2 ng/ml antigoat HRP-conjugated antibody or 1:1000 VEGFR-2 antibody (Cell Signalling #2479) and 2 ng/ml anti-rabbit HRP-conjugated antibody for 1 h each. Membranes were developed using supersensitive West Femto Maximum Sensitive Substrate (Pierce Biotechnology, Cramlington, Northumberland).
Blood pressure measurement
C57/Bl6 mice (>20 g) were deeply anaesthetised with sodium pentobarbitone (80 mg/kg, i.p.) and maintained airflexic throughout. The left external jugular vein was cannulated for supplementary anaesthetic (20-25 mg/kg/h, i.v.) and trachea intubated for maintenance of the airways. The left carotid artery was cannulated to allow blood pressure monitoring. Core body temperature (36-37 °C) was maintained throughout by means of a heating blanket connected to a rectal temperature probe, via an automatic feedback control unit. Following a period of time to allow blood pressure stabilisation, saline (vehicle, 100 μl) or rhVEGF 165 b (5 μg/100 μl) was infused through the external jugular vein and effects on blood pressure were monitored continuously.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software (version 3.0cx). Data are given as means ± s.e.m. or mean ± 95% confidence interval when stated. Half-lives were compared using 95% confidence intervals. One-way ANOVA followed by Bonferroni posthoc test was used to compare migration, liver enzyme levels, tumour weight and structure formations. Unpaired t-test and non-linear regression were used for k-values, vessel density and IC 50 calculation. One or two-way ANOVA was used to compare tumour growth in mice.
Results
Pharmacokinetic studies of circulating VEGF 165 b
Recombinant VEGF 165 b protein produced in CHO cells resulted in dimerisation and glycosylation of the protein (see Fig. 1A ). of approximately 1 nM (log IC 50 =-9.00 ± 0.18, log mean ± 95% confidence interval, see Fig. 1B ), similar to that observed with commercially produced protein or conditioned media. 6,7 The produced VEGF 165 b was stable, as incubation at 37 °C for two weeks did not alter the protein concentration or affect its activity (see Fig. 1C and inserted blot).
Pharmacokinetics and biodistribution
The pharmacokinetic parameters of VEGF 165 b were compared with conventional VEGF 165 .
To analyse circulating levels of VEGF 165 b, mice were injected with recombinant protein, and plasma was collected at different time points and analysed by ELISA. Intravenous injections of rcVEGF 165 b into the tail vein of mice showed that VEGF 165 b (see Fig. 2A ) had a circulating plasma half-life of 13 min, which was not significantly different from that for rcVEGF 165 (see Fig. 2A , VEGF 165 versus VEGF 165 b, p = 0.57, two-tailed Student's t-test). 
Biodistribution of intravenous VEGF 165 b
To determine how intravenously injected VEGF 165 b was distributed in vivo, 125 IrhVEGF 165 b was injected intravenously into tumour-bearing mice and imaged using highresolution single photon emission computed tomography (NanoSPECT/CT). Radiolabelled VEGF 165 b was distributed quickly through the mouse and images acquired at 40 min postinjection showed accumulation in the organs of metabolism and secretion. Thereafter, the overall signal gradually declines due to deiodination of the radiolabelled protein. Fig. 3A -C show whole body transverse, coronal and sagittal sections through the tumour acquired by 70 min post-injection. Uptake of radioactivity can be seen in the tumour as well as in the abdominal tissues such as liver and intestines; however, the image is dominated by accumulation of radioiodine into the thyroid, stomach and bladder indicating rapid dissociation of the radiolabelled iodine attached to the VEGF 165 b. This was confirmed by the analysis of urine which showed that only 10% of the activity was retained by a 10 kDa cut-off dialysis column, indicating that most of the excreted radioiodine was not proteinbound. In contrast, the proportion of low molecular weight iodine in tumours was similar to that in plasma (50%, data not shown). Collection of tumour and other tissues and measurement of biodistribution indicated that approximately 6% of the total 125 I-VEGF 165 b was found in the tumour at 4 h and was still detectable at 24 h (see Fig. 3D ). Of the nonsecretory organs, liver showed the highest uptake at 4 h.
Recombinant VEGF 165 b reduces tumour growth
We have previously shown that over-expression of VEGF 165 To determine whether intraperitoneal injection could inhibit tumour growth, two million colon carcinoma cells (LS174t) were injected subcutaneously into nude mice, and tumours were allowed to grow for 4 d before bi-weekly intraperitoneal injection of rhVEGF 165 b was initiated (Fig. 5B) . Treatment with rhVEGF 165 b significantly and dose dependently inhibited the growth of the established tumours compared with saline injection on day 10 for 50, 75
and 100 μg VEGF 165 b (p < 0.001, two-way ANOVA, n = 8, Fig. 5B ). The 100 μg dose resulted in a significantly greater inhibition of tumour volume on 14 d than the 75 μg dose (p < 0.001, two-way ANOVA, n = 8, Fig. 5B ). Analysis of the dose response curve at day 10
showed that the IC50 for the tumour inhibition was 48 μg.
These results show that injections of recombinant VEGF 165 b reduce the growth in vivo of heterotopic colon carcinoma tumours.
VEGF 165 b reduces spreading and vessel formation of endothelial cells on extracellular matrix
To explore the effect of VEGF 165 b on microvascular cells, an in vitro angiogenesis assay was used. Human dermal microvascular cells were seeded on an extracellular matrix gel containing 1 nM VEGF 165 , 1 nM VEGF 165 b, a combination of 1 nM VEGF 165 and 1 nM VEGF 165 b or media without growth factors or serum. As expected, cells stimulated with VEGF 165 produced extended vessel structures (see Fig. 6A ) quantified by increased branch points, sprouting structures and closed polygon structures (see Fig. 6C ). VEGF 165 b or the combination of VEGF 165 and VEGF 165 b reduced the cells ability to extend and form structures on the extracellular matrix (see Fig. 6B and C). This further indicates that VEGF 165 b has a direct effect on the endothelial cells along with reduced migration of HUVECs (see Fig. 1C ) and reduction in tumour growth by reduction of the microvessel density (see Fig. 4D ).
Accumulation and toxicology analysis
VEGF 165 b was shown to accumulate in the liver (see Fig. 3D ) and to determine whether VEGF 165 b had any negative effects on liver function, liver sections from mice receiving i.p. injections daily for 2 weeks were sectioned and stained. No apparent changes were seen in the morphology of the liver sections from mice injected with vehicle compared with mice injected with increasing amount of VEGF 165 b (see Fig. 7A ) even though intact VEGF 165 b protein was found (see Fig. 7B ). Mice were also closely monitored during the injection period by visual inspection, and no changes in behaviour, indications of inflammation or any other unusual observations were apparent. No significant difference was observed in the liver enzyme levels between i.p. VEGF 165 b injected and vehicle injected mice (see Fig. 7C , n = 3 mice per enzyme test, p > 0.05, one-way ANOVA), indicating that VEGF 165 b had no apparent adverse effects on liver function. Proteinuria was not seen after 100 μg bi-weekly i.p. injection (mean ± SEM urinary protein:creatinine ratios 32.6 ± 5.49 mg/mmol control compared with 32.6 ± 10.2 mg/mmol, VEGF 165 b).
VEGF 165 is known to rapidly induce hypotension after i.v. injection.12 Mice were injected with 5 μg rhVEGF 165 b i.v. and blood pressure was measured. No hypotension was observed (see Fig. 7D ).
Discussion
The anti-angiogenic isoform of VEGF, VEGF 165 b, is a potent inhibitor of blood vessel growth in ocular angiogenesis9 as well as in models of VEGF 165 -induced angiogenesis.7 VEGF 165 b levels are high in normal, non-angiogenic tissues, forming a substantial proportion or the majority of VEGF isoforms ( 13 and unpublished data). This family is downregulated or poorly expressed in angiogenesis-related conditions, both in physiological (e.g. in placenta14) and in pathological angiogeneses such as in tumours6,7, or diabetic retinopathy.13 As this is an endogenous anti-angiogenic isoform, the principle of restoring the balance of anti-versus pro-angiogenic isoforms in pathologies that are dependent on blood vessel growth is an attractive concept. 
